ストックスクリーナーアプリを入手
0.2306
1.11%
-0.0026
アフターアワーズ：
.23
-0.0006
-0.26%
前日終値:
$0.2332
開ける：
$0.23
24時間の取引高:
1.74M
Relative Volume:
1.43
時価総額：
$12.90M
収益：
-
当期純損益:
$-33.36M
株価収益率:
-0.3439
EPS:
-0.6706
ネットキャッシュフロー:
$-23.09M
1週間 パフォーマンス:
-70.26%
1か月 パフォーマンス:
-69.34%
6か月 パフォーマンス:
-67.09%
1年 パフォーマンス:
-80.78%
1日の値動き範囲:
$0.2251
$0.2444
1週間の範囲:
$0.2167
$0.80
52週間の値動き範囲:
$0.2167
$1.55
Pds Biotechnology Corp Stock (PDSB) Company Profile
名前
Pds Biotechnology Corp
セクター
電話
800-208-3343
住所
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corp
|
0.2306 | 13.53M | 0 | -33.36M | -23.09M | -0.6706 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Pds Biotechnology Corp Stock (PDSB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-11-01 | 開始されました | B. Riley Securities | Buy |
| 2021-06-28 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-11-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | 開始されました | Alliance Global Partners | Buy |
| 2020-03-09 | 開始されました | Noble Capital Markets | Outperform |
| 2019-10-24 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Pds Biotechnology Corp (PDSB) 最新ニュース
PDS Biotechnology shareholders approve charter amendment and director elections - Investing.com
Form 8K PDS Biotechnology Corp For: 14 August By Investing.com - Investing.com Nigeria
PDS Biotechnology (PDSB) wins approval to double authorized stock and elect directors - Stock Titan
PDS Biotechnology (PDSB) cuts R&D spend but warns on going concern, cash at $5.6M - Stock Titan
PDSB Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
PDS Biotechnology Q2 Results: EPS misses estimate, losses widen YoY - scanx.trade
Form 8K PDS Biotechnology Corp For: 13 August By Investing.com - Investing.com South Africa
PDS Biotechnology reports Q2 2026 net loss $9.8M, cash $5.6M, strategic refocus on PDS0301 - TradingView
PDS Biotech Reports $9.8 Million Second-Quarter 2026 Net Loss - Quiver Quantitative
PDS Biotech Reports Second Quarter 2026 Financial Results - The Manila Times
PDS Biotechnology: Q2 Earnings Snapshot - Barchart.com
PDS Biotechnology Corp (NASDAQ: PDSB) Share Price, PDSB Stock News, PDSB Share Price & Updates - Kalkine
PDS Biotech Prioritizes PDS0301 After 71% Response Rate In Colorectal Cancer And Discontinues PDS0101 Phase 3 Trial - Pulse 2.0
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.34% - Investing.com
PDS Biotechnology shifts focus to PDS0301, halts PDS0101 trial By Investing.com - Investing.com South Africa
PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program - Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Form 8K PDS Biotechnology Corp For: 11 August By Investing.com - Investing.com Nigeria
PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101 - manilatimes.net
PDS Biotechnology prioritizes PDS0301 after Phase 2 mCRC data, halts internal PDS0101 Phase 3 spend - TradingView
PDS Biotechnology shifts focus to PDS0301, halts PDS0101 trial - Investing.com
PDS Biotechnology Refocuses on PDS0301, Ends Internal Development of PDS0101 Phase 3 Trial - Quiver Quantitative
PDS0301 Data Show 80% 24-Month Survival With Liver Metastases - Stock Titan
PDS Biotechnology Corp (PDSB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PDS Biotechnology Corp expected to post a loss of 13 cents a shareEarnings Preview - TradingView
PDS Biotechnology Corp (PDSB) Stock News Today - TradingKey
PDS Biotechnology Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
PDSB|PDS Biotechnology Corp|Price:0.686|Chg%:-0.013 - TradingKey
PDS Biotechnology Corp (PDSB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PDS Biotechnology Corp (PDSB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PDS Biotechnology Corp (PDSB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PDSB|PDS Biotechnology Corp|Price:0.699|Chg%:+0.017 - TradingKey
PDS Biotechnology Corp (PDSB) Balance Sheet - TradingKey
PDS Biotechnology Corp (PDSB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PDS Biotechnology Corp (PDSB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PDSB Q1 2026 Earnings: Narrower-than-Expected Loss and Clinical Progress Drive FocusCapex Guidance - dars.gov.et
PDSB|PDS Biotechnology Corp|Price:0.775|Chg%:+0.028 - TradingKey
TradingKey - TradingKey
PDSB|PDS Biotechnology Corp|Price:0.720|Chg%:+0.039 - TradingKey
PDS Biotechnology Corp. Revenue Breakdown – FWB:EU6 - TradingView
PDS Biotechnology Corp SEC Filing (Jul 22, 2026) - Stock Titan
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.
PDS Biotechnology (PDSB) Shows Resilience with 5.95% Gain, Testing Key Resistance at $0.80Earnings Miss Risk - dars.gov.et
PDS Biotechnology (PDSB) Nears Critical Support as Shares Decline to $0.77Small Cap Breakouts - dars.gov.et
Form S-3 PDS Biotechnology Corp For: 10 July By Investing.com - Investing.com South Africa
PDS Biotechnology (NASDAQ: PDSB) registers 13.3M shares tied to note and warrant deal - Stock Titan
PDS Biotechnology (PDSB) Slides 4.6% as Selling Pressure Weighs on Biotech StockETF Inflow Streak - dars.gov.et
PDSB | PDS Biotechnology Corporation Common Executive Compensation - quiverquant.com
PDS Biotechnology (PDSB) Hovers Near Support Amid Modest DeclineVolume Breadth - dars.gov.et
PDS Biotechnology (NASDAQ: PDSB) details 2026 proxy votes and pay - Stock Titan
PDS Biotechnology Corp. Actuals & Estimates (NASDAQ:PDSB) - TradingView
Pds Biotechnology Corp (PDSB) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):